Treatment options for patients with uncontrolled hypertension
On-demand recorded 1 Jun 2021
High blood pressure (hypertension) is the worldwide leading preventable cause of death, primarily due to its strong association with increased risk for heart attack, stroke, heart failure, and kidney disease. Hypertension remains an ineffectively treated pandemic with a global prevalence of roughly 35%, with about 65% of cases uncontrolled. Lifestyle, patient preference and drug adherence all present challenges in controlling hypertension effectively.
Join this webinar to learn more about general drug therapy and approaches to interventional treatments as we explore the latest evidence in Renal Denervation and consider who may be the right patient for this treatment.
This event attracts 2 CPD points
This event is part of Medtronic 12 part webinar series. Events in this series are:
Dr Trish Kahawita
Trish is a new GP fellow who is passionate about digital health, medical education, and doctor wellbeing. She has been practicing medicine for the last ten years and has worked all around Australia, in both urban and remote areas. Her main clinical interests include Women's and Children's Health, Mental Health, Neurology, Geriatrics / Palliative Care, and Tropical Medicine. She has just moved to Sydney where she will work as a medical educator for GP Synergy as well as being a community Palliative Care GP. She also volunteers as a peer support facilitator for junior doctors. She is excited about the future of primary care and the use of innovative health technologies.
Professor Markus Schlaich
Renal physician and an ESH accredited hypertension specialist
Professor Schlaich is a renal physician and an ESH accredited hypertension specialist with a strong background in clinical research. His main scientific interests focus on pathophysiologic aspects of hypertension. Professor Schlaich has a specific interest in treatment modalities targeting the sympathetic nervous system and has contributed to the development of renal denervation as novel therapeutic approaches to hypertension. He has authored more than 325 articles and book chapters in peer reviewed journals and has received several research prizes and awards. He is the President of the High Blood Pressure Research Council of Australia and serves on the Council of the International Society of Hypertension and is Co-Chair of the Regional Advisory Group for North Asia, South-East Asia & Oceania. He is also a founding member of the ESH Working Group on Interventional Treatment of Hypertension. He is on the Editorial Board of Hypertension and Journal of Hypertension.